cladribine has been researched along with Fever in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chizuka, A; Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Tajima, K; Takaue, Y; Taniguchi, S; Usubuchi, N | 1 |
| Heldal, D; Juliusson, G; Lenkei, R; Liliemark, J; Tjønnfjord, G | 1 |
| Larson, RA; Mick, R; O'Brien, SM; Ratain, MJ; Spielberger, RT | 1 |
| Bosly, A; Delannoy, A; Ferrant, A; Filleul, B; Martiat, P; Michaux, JL; Mineur, P; Montfort, L; Straetmans, N; Van Den Neste, E; Vandercam, B | 1 |
| Adusumalli, J; Burian, C; Koziol, JA; Saven, A | 1 |
| Błasińska-Morawiec, M; Błoński, JZ; Robak, T; Skotnicki, AB; Urbańska-Ryś, H | 1 |
| Dmoszyńska, A; Kowal, M; Lech-Marańda, E; Robak, T; Wrzesień-Kuś, A | 1 |
2 trial(s) available for cladribine and Fever
| Article | Year |
|---|---|
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Chi-Square Distribution; Cladribine; Diarrhea; Digestive System Diseases; Drug Administration Schedule; Fatigue; Female; Fever; Hematologic Diseases; Humans; Immunocompromised Host; Infections; Infusions, Intravenous; Logistic Models; Lymphoproliferative Disorders; Male; Middle Aged; Treatment Outcome | 1996 |
Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Drug Administration Schedule; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Hairy Cell; Male; Middle Aged; Neutropenia; Recombinant Proteins | 1999 |
5 other study(ies) available for cladribine and Fever
| Article | Year |
|---|---|
Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Child; Child, Preschool; Cladribine; Female; Fever; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2004 |
Neutropenic fever following cladribine therapy for symptomatic hairy-cell leukemia: predictive factors and effects of granulocyte-macrophage colony-stimulating factor.
Topics: Cladribine; Female; Fever; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neutropenia; Risk Factors; T-Lymphocyte Subsets | 1995 |
Infectious complications after 2-chlorodeoxyadenosine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cladribine; Cohort Studies; Disease Susceptibility; Female; Fever; Hematologic Diseases; Herpesviridae Infections; Humans; Immunologic Deficiency Syndromes; Incidence; Infections; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Risk Factors; Waldenstrom Macroglobulinemia | 1996 |
2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger.
Topics: Adult; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cladribine; Cyclophosphamide; Doxorubicin; Drug Eruptions; Drug Resistance, Neoplasm; Female; Fever; Hematologic Diseases; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome; Vincristine | 1999 |
Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Neutropenia; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2000 |